Aura Biosciences Inc
NASDAQ:AURA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aura Biosciences Inc
NASDAQ:AURA
|
US |
|
C
|
Chia Chang Co Ltd
TWSE:4942
|
TW |
|
Shriram Finance Ltd
NSE:SHRIRAMFIN
|
IN |
|
R
|
Ratchaphruek Hospital PCL
SET:RPH
|
TH |
|
Encourage Technologies Co Ltd
TSE:3682
|
JP |
|
Wealthking Investments Ltd
HKEX:1140
|
HK |
|
S
|
SMC Global Securities Ltd
NSE:SMCGLOBAL
|
IN |
|
NIO Inc
NYSE:NIO
|
CN |
|
Addtech AB
STO:ADDT B
|
SE |
|
B
|
Beijing Shenzhou Aerospace Software Technology Co Ltd
SSE:688562
|
CN |
|
Nexity SA
PAR:NXI
|
FR |
Aura Biosciences Inc
Aura Biosciences, Inc. is a clinical-stage oncology company. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2021-10-29. The firm operates a platform, which focuses on ocular and urologic oncology. Its platform enables targeting of a range of solid tumors using Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDCs). The firm's VDC platform offers a range of portfolio of targeted oncology therapeutics. The company engaged in developing AU-011 for the treatment of early-stage disease, which includes small melanomas and indeterminate lesions. Its product candidate, AU-011 consists of a human papilloma virus (HPV)-derived VLP conjugated to thousands of infrared laser-activated molecules. VDC prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer (NMIBC).
Aura Biosciences, Inc. is a clinical-stage oncology company. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2021-10-29. The firm operates a platform, which focuses on ocular and urologic oncology. Its platform enables targeting of a range of solid tumors using Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDCs). The firm's VDC platform offers a range of portfolio of targeted oncology therapeutics. The company engaged in developing AU-011 for the treatment of early-stage disease, which includes small melanomas and indeterminate lesions. Its product candidate, AU-011 consists of a human papilloma virus (HPV)-derived VLP conjugated to thousands of infrared laser-activated molecules. VDC prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer (NMIBC).
